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there needs to be an appreciati
other clinicians that the studies
realistic comparators and clin
significant end points.
To facilitate physician engage
and training in clinical trials me
ology, the Australasian Socie
Infectious Diseases Clinical Res5) · 18 March 2013Objectives:  To determine research priorities of infectious diseases physicians 
for clinician-initiated randomised controlled trials (RCTs).
Design, setting and participants:  Online survey of infectious diseases 
physicians in Australia and New Zealand.
Main outcome measures:  Research priorities for, and perceived barriers to, 
clinician-initiated RCTs.
Results:  122/550 infectious diseases physicians (22%) responded to the survey. 
The five highest ranked proposals for clinician-initiated RCTs were in the areas 
of prosthetic joint infections, septic arthritis and osteomyelitis of native joints, 
Staphylococcus aureus bloodstream infections, diabetic foot infections and the 
treatment of serious multiresistant, gram-negative bacterial infections. Lack of 
funding was the most important perceived barrier to participation in clinician-
initiated RCTs.
Conclusions:  The research focus of infectious diseases physicians — optimal 
treatment of commonly encountered serious infections — highlights a lack of 
well conducted RCTs in this area.
Abstractan
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typ
effects o
R domised controlled trialsCTs) are accepted as the beste of study to assess the
f health care interventions
and therefore have a pivotal role in
evidence-based medicine.1 A new
paradigm is emerging whereby RCTs
are now being undertaken by a net-
work of clinicians.2
Clinician-initiated RCTs have sev-
eral features that differentiate them
from industry-sponsored studies.
They are more likely to compare
generically available, off-patent medi-
cations, or to study processes of care
or non-pharmacological interven-
tions. As clinician-initiated trials are
financially independent of industry,
with their funding source being gov-
ernmental research organisations (eg,
the National Health and Medical
Research Council [NHMRC]), the
results are viewed by clinicians as
more credible.3 The NHMRC has
already demonstrated a willingness to
fund clinician-initiated RCTs, as
shown by the success of networks
such as the Australian and New Zea-
land Intensive Care Society Clinical
Trials Group.4-7 The impact of their
successfully completed trials on prac-
tice  change, cost savings and
improved patient outcomes has not
been formally measured but is likely
to be significant.
Another key advantage is that clini-
cian-initiated RCTs tend to investi-
gate issues that clinicians find most
important and relevant to their prac-
tice. Moreover, the process of engage-
ment with other clinicians is a crucial
one. If investigator-initiated studies
are to successfully recruit patients,
on by
 have
ically
ment
thod-
ty for
earch
Network (ASID CRN) was estab-
lished in 2009. This report summa-
rises the results of an online survey of
infectious diseases physicians, con-
ducted by the ASID CRN, to establish
its research priorities.
Methods
In 2012, a self-reported online ques-
tionnaire-based survey was adminis-
tered on behalf of the steering group
of the ASID CRN. The survey was
developed by the ASID CRN steering
group, who compiled a list of more
than 100 potential studies: 42 poten-
tial randomised controlled trials, 20
epidemiological studies and 40 obser-
vational studies/registries. These
studies pertained to bacterial infec-
tions (69 of the nominated studies),
viral infections (18), fungal infections
(10), mycobacterial infections (3) and
general aspects of clinical infectious
diseases practice (3).
A “short list” of these studies was
selected by the ASID CRN steering
group to be sent to the entire commu-
nity of members of ASID, comprising
most practising infectious diseases
physicians in Australia and New Zea-
land. The ASID members were asked
to rate the proposed studies within
each group: (a) RCTs, (b) epidemio-
logical studies, and (c) registries of
specific infectious diseases, using a
numerical scale (with 1 being of little
likely clinical significance and 5 being
of greatest clinical significance).
To determine the feasibility of the
proposed studies, the physicians were
also asked to estimate the number of
patients seen at their hospital in the
past year with each of the conditions
relevant to the proposed clinical trial.
Additionally, they were asked to
describe barriers to enrolment of
study patients at their hospital.
Results
Of the 550 clinicians approached
online, 122 (22%) responded to the
survey. The RCTs ranked by the ASID
members as having most potential
clinical significance are listed in Box 1.
Foremost among these were RCTs
investigating prosthetic joint infec-
tions, native joint septic arthritis or
osteomyelitis, Staphylococcus aureus
bloodstream infections, foot infection
in diabetes and serious infections due
to gram-negative bacilli. Clinician
estimates of case loads per annum,
and hence the number of subjects
eligible for recruitment into these
studies, ranged from 600 to 700 for
the studies on prosthetic joint infec-
tion and gram-negative bacilli; 1000
to 2000 for those on native joint infec-
tions; and 2700 for foot infections in
diabetes.
ResearchThe surveyed clinicians also sup-
ported further study of emerging
infections (eg, multi- or extensively
drug-resistant tuberculosis or unex-
plained encephalitis) by way of regis-
tries or epidemiological studies.
Barriers to performance of clinician-
initiated studies are listed in Box 2. The
most commonly perceived barrier was
lack of funding for conducting studies,
followed by absence of infrastructure
or study personnel, and lack of time
owing to clinical commitments.
Discussion
A number of features dominated the
research preferences of Australian
and New Zealand infectious diseases
physicians. RCTs investigating opti-
mal treatment of commonly encoun-
tered infections were highly ranked,
highlighting the lack of well con-
ducted RCTs in this area. Investiga-
tions  into optimal therapy  of
antibiotic-resistant organisms were
also identified as a priority.
C l ini c ian- in i t i a ted  re search
presents a number of advantages over
research sponsored by pharmaceutical
companies. The primary focus of clini-
cian-initiated research is to answer
problems of direct clinical relevance,
while that of pharmaceutical compa-
nies is to obtain regulatory approval
for new, patented products. Addition-
ally, the impact of clinician-focused
research is, in many cases, cost-sav-
ings to the health care system, while
that of company-initiated research is
the introduction of new and often
expensive drugs or devices. As an
example, the four highest-ranked
RCTs proposed by Australian and
New Zealand infectious diseases phy-
sicians dealt with reducing the dura-
tion of courses of intravenous
antibiotics (Box 1). RCTs whereby
medications are used less are unlikely
to be of interest to industry. RCTs that
allow the rigorous evaluation of
recommendations in guidelines are
likely to be of particular value to clini-
cians, and those that reduce the dura-
tion of intravenous antibiotic courses
are likely to reduce costs for govern-
ments and, potentially, reduce
adverse events for patients.
Steering groups, comprising both
researchers and clinicians, have now
been established to develop proto-
cols, seek funding for the trials and
initiate the studies most highly
ranked by clinicians.
Could the methodology and results
of our survey of infectious diseases
physicians be of use to other clini-
cians? More than 90 research net-
works of collaborating clinicians
currently exist in Australia (http://
australianclinicaltrials.gov.au/). Some
of these networks are well established
and have been highly productive,
completing a number of high-impact
studies.4-9 Others are nascent, like
our own, and may seek to replicate
our methodology.
There are significant challenges in
the initiation and conduct of clinician-
initiated studies. Foremost of these is
funding, which was regarded in our
survey as the single largest barrier to
studies being conducted. Other
potential difficulties included time-
consuming processes for (and cost of)
ethical approval, and lack of support
and infrastructure in cash-strapped
hospital systems. Innovative solutions
to these barriers should be sought —
other research networks (eg, Austral-
ian and New Zealand Intensive Care
Society Clinical Trials Group) have
received funding from foundations
1 Proposals for randomised-controlled trials ranked highest for clinical significance 
by infectious diseases physicians
Mean score* Protocol title 
1 3.97 Early prosthetic joint infections managed with debridement and 
retention: 6 weeks of intravenous antibiotics versus 2 weeks of 
intravenous antibiotics and prolonged oral antibiotics
2 3.83 Native joint septic arthritis or osteomyelitis: 6 weeks of intravenous 
antibiotics versus 2 weeks of intravenous antibiotics and prolonged oral 
antibiotics
3 3.82 Uncomplicated Staphylococcus aureus bloodstream infections: 2 weeks 
of intravenous antibiotics versus 1 week of intravenous antibiotics and 1 
week of oral antibiotics
4 3.74 All oral antibiotic regimen versus prolonged intravenous antibiotics for 
diabetic foot infection 
5 3.43 Meropenem versus piperacillin–tazobactam for serious infections caused 
by an extended-spectrum -lactamase producer
6 3.38 Enterococcal endocarditis: ampicillin–gentamicin versus ampicillin/
ceftriaxone
7 3.30 Fosfomycin versus ertapenem for urinary tract infections caused by an 
extended-spectrum -lactamase producer
8 3.26 Daptomycin versus vancomycin for methicillin-resistant S. aureus 
bloodstream infections with a minimum inhibitory concentration of 
vancomycin of 2 mg/L
9 3.25 Short (2-day) versus standard (5-day) intravenous treatment for cellulitis
10 3.23 14-day versus 7-day antibiotic course for bloodstream infections caused 
by gram-negative bacilli
11 3.11 -lactam plus aminoglycoside combination therapy versus -lactam 
monotherapy for serious Pseudomonas aeruginosa infections
12 3.09 Topical versus topical plus systemic decolonisation regimen for patients 
with recurrent S. aureus infections
13 2.75 Extended/continuous infusion versus bolus infusion of -lactam therapy 
for infections in patients with neutropenia
* Surveyed infectious diseases physicians were asked to rank each study proposal on a scale of 1–5 
(1 = of little likely clinical significance; 5 = of greatest clinical significance). The mean score of 122 
surveyed clinicians is given. ◆
2 Ranking of perceived obstacles to clinician-initiated research by infectious 
diseases physicians
Mean score* Perceived obstacle
1 4.26 Lack of funding
2 4.00 Lack of study nurse/coordinator
3 3.92 Limitations of time owing to excessive clinical load
4 2.72 Difficulties with submissions to ethics committees
5 2.67 Difficulties with clinicians in other specialties
* Surveyed infectious diseases physicians were asked to rank obstacles to clinical research on a scale 
of 1–5 (1 = of no importance; 5 = of greatest importance). The mean score of 122 surveyed clinicians is 
given. ◆271MJA 198 (5) · 18 March 2013
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MJA 198 (272and the NHMRC. In addition, the
private hospital system may be an
untapped resource for clinician and
administrative support.
A limitation of our study was the
low response rate of 22%. This is to be
expected given the nature of online
surveys. The research priorities cho-
sen may not necessarily reflect those
of all members of ASID.
We have described here a method
for giving practising clinicians a cen-
tral role in the selection of clinical
studies. We hope that this will facili-
tate not just the planning and conduct
of these studies, but also their rapid
implementation into clinical practice.
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